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Abstract
Objective Metoclopramide is the only medication widely
used to promote gastrointestinal motility in the USA. De-
spite its appreciable risk of central nervous system com-
plications, it continues to be prescribed to children for
chronic use. We sought to estimate the prevalence of
chronic metoclopramide use among US children and
identify the diagnoses that may have prompted this use.
The US metoclopramide label lists only two indications in
adults: symptomatic gastroesophageal reflux (GERD) and
diabetic gastroparesis. The latter is rare in children so, in
examining the indications likely to have prompted chronic
metoclopramide use, we focused on GERD.
Methods From two health services databases representing
privately and publically insured children, respectively, we
estimated the number of US children who used metoclo-
pramide chronically and identified the diagnoses recorded
at approximately the time when the chronic use began. We
defined chronic use liberally as C35 days’ supply, or
conservatively as C130 days’ supply in a 6-month period.
For each chronic-use definition, insurance type, and age
group, we estimated the proportion of children using me-
toclopramide chronically. We applied these proportions to
US population estimates.
Results Under the liberal and conservative definitions,
respectively, 89,020 and 28,222 US children used meto-
clopramide chronically.
Conclusion In spite of its risk, substantial numbers of US
children use metoclopramide chronically for symptoms
suggestive of GERD.
Key Points
Metoclopramide, the only gastrointestinal motility
agent widely used in the USA, has a black-box
warning for tardive dyskinesia.
We found that, nonetheless, it is used chronically by
at least 28,000 US children, most of whom have at
least one health service claim for symptomatic
gastroesophageal reflux (GERD).
This suggests a perception that many US children
with symptoms suggestive of GERD are not
adequately treated by lifestyle changes and acid
suppression.
1 Introduction
Metoclopramide, the only gastrointestinal (GI) motility
agent that is widely used in the USA, crosses the blood–brain
barrier and is associated with central nervous system (CNS)
side effects, including irritability, tardive dyskinesia, and
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lowering of the seizure threshold [1]. Its label includes a
black-box warning for tardive dyskinesia and a statement
that extrapyramidal symptoms occur more frequently in
pediatric patients and adult patients less than 30 years of age.
Two clinical reviews on metoclopramide treatment of gas-
troparesis report tardive dyskinesia in 1–15 % of treated
patients, although there is no prospective data on this risk [2,
3]. This suggests that prescription of metoclopramide to
children for chronic use reflects a perception of a substantial
need that is not met by other medications available in the
USA. We sought to estimate the prevalence of chronic me-
toclopramide use among US children and identify the diag-
noses that may have prompted its use.
The prescribing information in the US Package Insert
(USPI) for oral metoclopramide lists two indications for
adults only: symptomatic gastroesophageal reflux (GERD)
and diabetic gastroparesis [4, 5]. Because the latter is rare
among children, we focused on the former. The prevalence
of refractory GERD in the pediatric population is suspected
to be low, but is not well documented, and for those af-
fected, the need for effective chronic treatment is great.
Therefore it is of interest to have a better understanding of
the prevalence of this condition among children.
A diagnosis of GERD recorded in a claims database
does not mean the patient met the formal criteria for the
diagnosis. He or she may simply have had symptoms
suggestive of the diagnosis. However, the recording of the
diagnosis in the database, together with the prescription of
metoclopramide for chronic use and the concurrent pre-
scription of an acid suppressing medication, strongly sug-
gests the prescribing physician found chronic GERD to be
a credible cause of the patient’s symptoms and found those
symptoms to be unresponsive to more conservative treat-
ment, including changes in feeding and positioning, and the
use of acid suppressive medications only [6, 7]. This study
directly estimates the prevalence of chronic metoclo-
pramide use in US children under either of two definitions
of chronic use.
Furthermore, refractory GERD in children can be de-
fined as the persistence of symptoms and esophageal in-
flammation beyond 1 year of age in spite of the chronic
application of accepted feeding and lifestyle changes and
medical intervention with the standard of care [acid sup-
pression with histamine 2 receptor antagonists (H2RAs)
and/or proton pump inhibitors (PPIs)]. In this study, the
number of children aged [1 year who used metoclo-
pramide chronically and had a diagnosis of GERD at about
the time they began its chronic use approximates, but does
not strictly meet, these criteria.
Refractory GERD has a markedly increased prevalence
among children who have certain underlying conditions,
including CNS dysfunction; congenital genetic/metabolic
conditions, for example, Down syndrome, Rett syndrome,
Cornelia de Lange syndrome; chronic pulmonary disease
such as cystic fibrosis and chronic asthma; and repaired
esophageal atresia, trachea-esophageal fistula or congenital
diaphragmatic hernia [8]. Especially among those with
severe CNS dysfunction, motility abnormalities often per-
sist even after treatment of GERD with acid suppressive
agents [9]. Because the prescription of metoclopramide for
chronic use in such patients seemed likely to reflect
symptoms similar to those of GERD, even if the diagnosis
of GERD was not entered into the claims database, we
tabulated separately the numbers of children in the data-
base who used metoclopramide chronically, had a diag-
nosis suggestive of an underlying condition with a high risk
of GERD, but did not have a diagnosis of GERD, at ap-
proximately the time they began chronic use of
metoclopramide.
2 Methods
We used two large healthcare claims databases [Truven
Health MarketScan Multi-State Medicaid and Truven
Health MarketScan Commercial Claims and Encounters
(CCAE) databases]. The CCAE is representative of a pri-
vately insured population and the Medicaid database con-
tains data on Medicaid enrollees from multiple states, but
not all states. The version of CCAE we used for this study
described over 90 million members with medical and
pharmacy coverage. The Medicaid data reflected over
9 million members enrolled between January 2006 and
January 2009 in states that shared these data with Truven
Health Analytics. The mean age in the CCAE population
was 31.3 years; 49 % of the population was male; and the
average duration of observation in the database was
2.3 years. The mean age in the Medicaid population was
17.0 years; 42 % of the population was male; and the av-
erage duration of observation in the database was
1.5 years. These databases capture diagnoses and proce-
dures submitted for office visits and hospitalizations and
also capture prescription drug dispensing in retail and mail-
order pharmacies. The New England Institutional Review
Board (NEIRB# 12-284) has determined that studies con-
ducted in the databases used in this study do not meet the
definition of human subjects research.
2.1 Identifying the Cohort
We first identified a cohort of patients who were either
continuously enrolled in each database for the 2-year period
from July 1, 2007 to June 30, 2009 (except for gaps of less
than 32 days) or, for those born during July 2007 through to
the end of December 2008, were enrolled since birth. This
defines the population in which our study is nested. Cohort
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members were children B17 years old during the period
January 1, 2008–December 31, 2008. Within this group, we
identified the subjects with chronic metoclopramide use,
defined the index date for each such subject as the date of the
first metoclopramide dispensing in 2008, and looked for di-
agnoses near the index date that could be reasons for that
subject’s chronic metoclopramide use.
2.2 Identifying Metoclopramide Users
The observation window for metoclopramide use began
with the date of the first metoclopramide dispensing in
2008 and continued for 6 months (183 days). Users were
defined as anyone with at least one dispensing of a meto-
clopramide preparation for oral use in 2008. Two alterna-
tive definitions of chronic user were based on the number
of dispensings and days’ supply dispensed, starting with,
and including, the first metoclopramide dispensing to each
child in 2008. Requiring a minimum of two dispensings of
metoclopramide increases the likelihood that at least one of
those dispensings was consumed:
1. More restrictive definition Chronic use required at
least two dispensings and a minimum of 130 days’
supply in the 183 days from the initial dispensing.
2. Less restrictive definition Chronic use required at least
two dispensings and a minimum of 35 days’ supply in
the 183 days from the initial dispensing.
Because dispensings with [90 days’ supply were not
considered plausible, only dispensings with 90 days’ sup-
ply or less were included. If there were multiple dispens-
ings of metoclopramide on the same day, only the largest
days’ supply was included in the total days’ supply. This
rule was applied because patients could get multiple pre-
scriptions of different dose sizes to add up to the necessary
dose. Finally, any days’ supply that would have been taken
after the patient’s 183-day follow-up period was censored
(e.g., if a patient received a prescription on March 12, 2008
for 30 days’ supply, but the end of their follow-up was on
March 13, 2008, the days after March 13 would not be
included in their total days’ supply of metoclopramide).
2.3 Identifying Diagnoses
For all cohort members, GI-related diagnoses were ob-
tained by searching the time period from 183 days prior to
the index date through to 183 days following the index
date. For cohort members with less than the full 183-day
lead-in period (i.e., for those who were aged under
2 years), the search window started with the enrollment
date and ended 183 days after the index date.
To better understand the characteristics of the popula-
tion of pediatric metoclopramide users, we defined broad
GI-related categories that include diagnoses for which
metoclopramide might be used. The three broad but non-
overlapping diagnosis categories were (1) a diagnosis of
GERD; (2) GI diagnoses other than GERD, but possibly
related to GERD; and (3) neurogastroenterology (neuro-
GI) diagnoses of conditions with a known increased risk of
chronic GERD. The International Classification of Dis-
eases, Ninth Revision (ICD-9) diagnoses codes in each
category are listed in Online Resource Table A1. GERD
was defined by having a diagnostic code for either reflux
esophagitis or esophageal reflux. Common examples for
‘‘GI diagnoses’’ other than GERD, but possibly related to
GERD, include gastroparesis, vomiting, asthma, chest pain,
pneumonia and cystic fibrosis. The ‘‘neuro-GI diagnoses’’
were neurological or CNS conditions that could be ac-
companied by GI comorbidities for which metoclopramide
may be prescribed, such as cerebral palsy, Down syn-
drome, and epilepsy. Although the categories did not
overlap in the sense that no diagnosis appeared in more
than one category, it was possible for a patient with mul-
tiple diagnoses to appear in more than one category.
2.4 Estimating the Number of Chronic
Metoclopramide Users in the US Pediatric
Population
Assuming the databases are representative of privately and
Medicaid insured people in the USA, and that all children
are covered by private insurance or Medicaid eligible, the
rates in the databases could be applied to estimates of the
corresponding Medicaid and privately insured populations
to generate estimates for overall chronic metoclopramide
use. Estimates for the number of privately insured children
aged 17 or less in the USA were obtained by subtracting
the number of Medicaid eligible in the USA in 2008 [10]
from US census population counts [11] for that year (see
Online Resource Tables A2 and A3). Within each age
group,\1, 1, 2–6, and 7–17 years, the proportion of chil-
dren in each database who were chronic users was then
applied to the corresponding privately insured and Medi-
caid populations. To confirm that we had identified the
population of interest for our study with symptoms sug-
gestive of GERD, we also examined the use of H2RAs and
PPIs during the follow-up period. Specifically, we identi-
fied the number and proportion of children who took me-
toclopramide chronically and had a dispensing of either an
H2RA drug or a PPI that overlapped with the metoclo-
pramide dispensing on the index date and/or the 183-day
follow-up.
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3 Results
Table 1 shows how the criteria applied to each database
resulted in the cohorts of privately and publically insured
patients, respectively. In the private insured database, there
were 7,086,142 children aged B17 during the study period
and 3,076,597 met the study entry criteria of continuous
enrollment during July 1, 2007 through to June 30, 2009,
except for gaps of less than 32 days. Similarly, in the
Medicaid database there were 3,119,150 children aged B17
during the study period and 1,060,030 met the study entry
criteria of continuous enrollment during July 1, 2007
through to June 30, 2009, except for gaps of less than
32 days. In each age group, less than 2 % were metoclo-
pramide users and less than 1 % were chronic metoclo-
pramide users.
Tables 2 and 3 give the percentage of the study cohorts
with a diagnosis ofGERD,with broadly relatedGI diagnoses
Table 1 Identification of eligible patients in the Truven Health MarketScan Commercial Claims and Encounters (CCAE) and Multi-State
Medicaid databases
CCAE (n) Medicaid (n)
All children aged 0–17 during July 1, 2007–June 30, 2009 7,086,142 3,119,150
Study entry criteria: children continuously enrolled (except for gaps\32 days)
from July 1, 2007 to June 30, 2009, or since birth for those born during
July 2007 through to the end of December 2008
3,076,597 1,060,030
No. with at least 1 metoclopramide dispensing during 2008 and days’ supply B90 7128 7126
No. with at least 2 metoclopramide dispensings 2757 3412
Chronic use (unrestrictive): no. with 35 days’ supply 2295 2986
Chronic use (restrictive): no. with 130 days’ supply 668 848
Table 2 Number of children with GI-relateda diagnoses among chronic users of metoclopramide, Truven Health MarketScan Commercial
Claims and Encounters database
Diagnosis Total cohort Non-users Usersb Chronic (35 days)c Chronic (130 days)
Age\ 1 year
Total cohort size 192,560 (100 %) 190,597 (100 %) 1963 (100 %) 900 (100 %) 226 (100 %)
GERD 22,002 (11.43 %) 20,478 (10.74 %) 1524 (77.64 %) 729 (81.00 %) 190 (84.07 %)
GI diagnoses 16,487 (8.56 %) 15,788 (8.28 %) 699 (35.61 %) 319 (35.44 %) 80 (35.4 %)
Neuro-GI disorders 34,921 (18.14 %) 34,242 (17.97 %) 679 (34.59 %) 340 (37.78 %) 99 (43.81 %)
Age 1 to\2 years
Total cohort size 220,597 (100 %) 219,223 (100 %) 1374 (100 %) 593 (100 %) 178 (100 %)
GERD 9393 (4.26 %) 8545 (3.90 %) 848 (61.72 %) 466 (78.58 %) 142 (79.78 %)
GI diagnoses 22,539 (10.22 %) 21,995 (10.03 %) 544 (39.59 %) 237 (39.97 %) 74 (41.57 %)
Neuro-GI disorders 14,504 (6.57 %) 14,106 (6.43 %) 398 (28.97 %) 228 (38.45 %) 81 (45.51 %)
Age 2–6 years
Total cohort size 689,070 (100 %) 688,227 (100 %) 843 (100 %) 248 (100 %) 108 (100 %)
GERD 6035 (0.88 %) 5745 (0.83 %) 290 (34.4 %) 162 (65.32 %) 76 (70.37 %)
GI diagnoses 55,668 (8.08 %) 55,283 (8.03 %) 385 (45.67 %) 140 (56.45 %) 63 (58.33 %)
Neuro-GI disorders 17,967 (2.61 %) 17,780 (2.58 %) 187 (22.18 %) 123 (49.6 %) 69 (63.89 %)
Age 7–17 years
Total cohort size 1,974,370 (100 %) 1,971,422 (100 %) 2948 (100 %) 554 (100 %) 156 (100 %)
GERD 17,165 (0.87 %) 16,420 (0.83 %) 745 (25.27 %) 287 (51.81 %) 82 (52.56 %)
GI diagnoses 76,965 (3.9 %) 75,707 (3.84 %) 1258 (42.67 %) 305 (55.05 %) 82 (52.56 %)
Neuro-GI disorders 39,536 (2.00 %) 39,119 (1.98 %) 417 (14.15 %) 158 (28.52 %) 64 (41.03 %)
GERD symptomatic gastroesophageal reflux, GI gastrointestinal, Neuro-GI neurogastroenterology
a Note that patients could be assigned to multiple diagnostic groups
b The last three columns are nested. Users includes all chronic users
c Chronic users with 130 days’ supply were included in with the chronic users with at least 35 days’ supply
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not including GERD, and with neuro-GI diagnoses not in-
cluding GERD, and for each age group for the CCAE and
Medicaid database populations, respectively. In each data-
base and for either definition of chronic use, 2–4 % of
chronic metoclopramide users carried a diagnosis of gas-
troparesis (numbers not shown). Reading across rows in both
tables, the percentages with diagnoses were higher among
metoclopramide users compared with non-users, and highest
amongst those with chronic metoclopramide use, as would
be expected. Among privately insured andMedicaid-insured
subjects, the proportion of chronic users who had a diagnosis
of GERD was approximately 80 % in those\2 years of age,
60–70 % in those aged 2–6 years, and 50 % in those aged
7–17 years. For all ages combined, 70–75 %of chronic users
had a diagnosis of GERD (numbers not shown). As age in-
creased, the percentage of chronic users with a diagnosis of
GERD decreased and the percentage with other GI-related
diagnoses increased. Because the number of chronic users of
metoclopramide per year of age decreased substantially with
age (e.g., the number per year of age in age group 2–6 years
is the number in the table divided by 5), the number of
children per year of age who had other GI diagnoses did not
increase with age.
Substantial proportions of chronic users (approximately
40–60 %) had broad GI-related or neuro-GI diagnoses in
each age group in both the Medicaid and privately insured
populations (Tables 2 and 3). In the Medicaid population,
the percentage of chronic users with neuro-GI conditions
was substantially higher among those aged[1 year than
among those aged B1 year. Additionally, over 87 % of
chronic users (either type) who were privately insured had
at least one of the three types of GI diagnoses in the tables
(numbers not shown). For Medicaid insured children, over
90 % of chronic metoclopramide users had at least one of
these GI diagnosis types.
We also examined the extent of concomitant use of
H2RAs and PPIs with metoclopramide. Concomitant use
was defined as an overlap of at least 1 day based on dis-
pensing date and days’ supply. Regardless of diagnostic
category, more than 60 % of children who took metoclo-
pramide chronically took concomitantly a medication that
suppressed gastric acid. Among those with a diagnosis of
GERD and the less restrictive definition of chronic meto-
clopramide use, over 85 % also had concomitant dispens-
ing of a gastric acid suppressor in both databases (data not
shown). And for those with a diagnosis of GERD and the
Table 3 Number of children with GI-related diagnosesa among chronic users of metoclopramide, Truven Health MarketScan Multi-State
Medicaid database
Diagnosis Total cohort Non-users Usersb Chronic (35 days)c Chronic (130 days)
Age\ 1 year
Total cohort size 180,277 (100 %) 177,100 (100 %) 3177 (100 %) 1356 (100 %) 267 (100 %)
GERD 26,014 (14.43 %) 23,531 (13.29 %) 2483 (78.16 %) 1180 (87.02 %) 233 (87.27 %)
GI diagnoses 29,108 (16.15 %) 27,717 (15.65 %) 1391 (43.78 %) 646 (47.64 %) 124 (46.44 %)
Neuro-GI disorders 32,157 (17.84 %) 31,026 (17.52 %) 1131 (35.6 %) 575 (42.4 %) 125 (46.82 %)
Age 1 to\2 years
Total cohort size 130,976 (100 %) 129,747 (100 %) 1229 (100 %) 531 (100 %) 140 (100 %)
GERD 6,898 (5.27 %) 6072 (4.68 %) 826 (67.21 %) 446 (83.99 %) 117 (83.57 %)
GI diagnoses 24,088 (18.39 %) 23,405 (18.04 %) 683 (55.57 %) 306 (57.63 %) 86 (61.43 %)
Neuro-GI disorders 11,931 (9.11 %) 11,413 (8.8 %) 518 (42.15 %) 306 (57.63 %) 104 (74.29 %)
Age 2–6 years
Total cohort size 262,939 (100 %) 262,057 (100 %) 882 (100 %) 452 (100 %) 186 (100 %)
GERD 4562 (1.74 %) 4089 (1.56 %) 473 (53.63 %) 325 (71.9 %) 128 (68.82 %)
GI diagnoses 35,928 (13.66 %) 35,421 (13.52 %) 507 (57.48 %) 267 (59.07 %) 107 (57.53 %)
Neuro-GI disorders 20,684 (7.87 %) 20,203 (7.71 %) 481 (54.54 %) 338 (74.78 %) 160 (86.02 %)
Age 7–17 years
Total cohort size 485,838 (100 %) 484,000 (100 %) 1838 (100 %) 647 (100 %) 255 (100 %)
GERD 8648 (1.78 %) 8038 (1.66 %) 610 (33.19 %) 371 (57.34 %) 148 (58.04 %)
GI diagnoses 40,007 (8.23 %) 39,118 (8.08 %) 889 (48.37 %) 327 (50.54 %) 120 (47.06 %)
Neuro-GI disorders 34,670 (7.14 %) 34,093 (7.04 %) 577 (31.39 %) 382 (59.04 %) 192 (75.29 %)
GERD symptomatic gastroesophageal reflux, GI gastrointestinal, Neuro-GI neurogastroenterology
a Note that patients can be assigned to multiple diagnostic groups
b The last three columns are nested. Users includes all chronic users
c Chronic users with 130 days’ supply were included in with the chronic users with at least 35 days’ supply
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more restrictive definition of chronic metoclopramide use,
over 90 % also had concomitant dispensing of a gastric
acid suppressor in both databases (data not shown).
Table 4 presents estimates of the total number of US
children with chronic use of metoclopramide for each
definition of chronic use by age group. Numbers were
based on population estimates and the percentage of
chronic users from each of the databases. Using the 35-day
criterion for chronic use of metoclopramide, 89,020 US
children used metoclopramide chronically. Of these, ap-
proximately 70 % were Medicaid insured, and 45 % were
\2 years old. Using the 130-day criterion for chronic use
of metoclopramide, 28,222 US children used metoclo-
pramide chronically. Of these, approximately three-quar-
ters were Medicaid insured and 33 % were\2 years old.
4 Discussion
This study used two large healthcare claims databases rep-
resenting privately insured and Medicaid populations, re-
spectively, to calculate population-based estimates of chronic
metoclopramide use in children aged 17 or less and describe
the prevalence of diagnoses likely to be the reasons for this
use. Chronic use required at least two dispensings. While it
is possible they were filled but not used, taking the trouble
and expense of filling a prescription twice suggests that the
medication was used. Among this study’s limitations was (1)
the assumption that children who were not Medicaid insured
were privately insured, effectively grouping any uninsured
children with the privately insured. This resulted in a
conservative estimate in the sense that privately insured
children had lower rates of chronic use than did Medicaid
insured children, but may have yielded an over-estimate to
the extent that there were uninsured children who had no
access to care. (2) Although it is unlikely for anyone to have
private insurance and Medicaid insurance in the same
6-month period, there is no way to identify patients who may
appear in both databases. (3) A diagnosis of GERD in the
medical record at approximately the time that a child began
chronic metoclopramide use, and a high prevalence of acid
suppressive medication use among these children does not
demonstrate that these children met the criteria for treatment-
resistant GERD, though it strongly suggests that metoclo-
pramide was being used to treat symptoms suggestive of
GERD that did not respond adequately to more conventional
treatment. An alternative explanation is that metoclopramide
was used for symptoms of chronic non-GERD-related nau-
sea, vomiting or delayed gastric emptying that may or may
not have been associated with GERD, but for the patients
with a diagnosis of GERD, there was a high prevalence of
acid-suppressing medication use and reason to believe that
some caregiver thought this was a credible diagnosis.
Chronic users were characterized according to three broad
GI-related groups that might account for their use of metoclo-
pramide: (1) a diagnosis of GERD, (2) GI diagnoses other than
GERD, such as gastroparesis and vomiting, and (3) neuro-GI
diagnoses other than GERD, but known to be associated with a
high risk of chronic GERD, such as cerebral palsy. The largest
subgroup of patients was those with a diagnosis of GERD,
accounting for 52–87 % of chronic users regardless of use
definition, depending on age.
Table 4 Estimated US prevalencea of pediatric population with chronic metoclopramide use, by insurance type and age group
Chronic use (C35 days): age group Chronic use (C130 days): age group
\1 year 1 year 2–6 years 7–17 years Total:
age
0–17




2008 population 2,415,672 2,064,288 9,523,468 15,188,287 2,415,672 2,064,288 9,523,468 15,188,287
Chronic use
(% of population)
0.75 0.41 0.17 0.13 0.15 0.11 0.07 0.05
Prevalence
chronic use
18,170 8369 16,371 20,227 63,137 3578 2207 6737 7972 20,494
Privately insured
2008 population 1,717,063 2,036,468 10,526,582 30,632,774 1,717,063 2,036,468 10,526,582 30,632,774
Chronic use
(% of population)
0.47 0.27 0.04 0.03 0.12 0.08 0.02 0.01
Prevalence
chronic use
8025 5474 3789 8595 25,883 2015 1643 1650 2420 7728
Total with
chronic use
26,195 13,843 20,160 28,822 89,020 5593 3850 8387 10,392 28,222
a Due to rounding, the population counts multiplied by percentages do not exactly match the estimates
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In both databases, the percentage of chronic users of
metoclopramide who also had a diagnosis of GERD de-
creased from the youngest to the oldest age groups. There
may be several explanations for this phenomenon. Higher
chronic use in the youngest patients with a diagnosis of
GERD may reflect an effort to avoid the need for anti-reflux
surgery by using both acid suppression plus a prokinetic
agent in addition to the standard adjustments in the method
and type of feeding [6, 7].Older age groupsmay be less likely
to use metoclopramide chronically because, either their
symptoms may ameliorate with age, or adverse events in-
cluding irritability and dystonic reactions may discourage
chronic use, or GERD surgery, if successful, may make
medications that treat reflux unnecessary.
5 Conclusion
This study indicates that, though other agents such as ery-
thromycin, or, by special arrangements, cisapride or dom-
peridone, are used for treatment of GI motility disorders [5,
12], between 28,222 and 89,020 US children aged 17 or
younger chronically use metoclopramide even with its
relatively high-risk adverse event profile. Chronic use of
metoclopramide in childrenwith a diagnosis ofGERD ismore
prevalent in children aged\1 year and decreases in older age
groups. However, a higher percentage of older patients have
neurological impairment accompanying their GERD when
they use chronic metoclopramide compared with younger
children. The substantial amount of prescribing of metoclo-
pramide for chronic use appears to reflect a perception that
prokinetic agents may be useful when added to acid-sup-
pressive treatment of some children with chronic symptoms
consistent with refractory GERD, and a perception that there
is a need for prokinetic drugs for this population.
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